Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $28.3200 (-0.91%) ($27.8000 - $28.7300) on Thu. Dec. 31, 2015. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 10.87% (three month average) | RSI | 86 | Latest Price | $28.3200(-0.91%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -1.7% a day on average for past five trading days. | Weekly Trend | ADMS advances 42.1% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(32%) IBB(30%) ARKG(22%) XOP(22%) IWO(21%) | Factors Impacting ADMS price | ADMS will decline at least -5.435% in a week (0% probabilities). VIXM(-14%) BNDX(-10%) TLT(-7%) UUP(-6%) SHY(-6%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -5.435% (StdDev 10.87%) | Hourly BBV | 0 () | Intraday Trend | -0.9% | | | |
|
5 Day Moving Average | $29.11(-2.71%) | 10 Day Moving Average | $24.29(16.59%) | 20 Day Moving Average | $20.07(41.11%) | To recent high | -8.2% | To recent low | 112.5% | Market Cap | $801m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |